The Society of MSK Campaign 2023–2024

Advancing Lymphoma Research at MSK

Chairs
Veronica Swanson Beard
Gillian Hearst
Kamie Lightburn
Stephanie Loeffler
Emilia Fanjul Pfeifler
Naomi Waletzky

Associates Chairs
Julia Amory
Melissa Crandall
Austen Cruz
Beth Blake Day
Mary Carlisle Gambill

Executive Committee Chairs
Travis Acquavella
Muffie Potter Aston
Claire Capello
Robyn Joseph
Jessie Kisling
Karen Thornwell May
Palmer Jones O’Sullivan
Memorial Sloan Kettering Cancer Center (MSK) is home to one of the world's largest and most innovative research and clinical trial programs focused on lymphoma, a cancer that develops in the lymphocyte, a type of white blood cell essential to fighting infection. As research has accelerated over the past two decades, more than 80 subtypes of lymphoma have been discovered and an array of new drugs has been approved to treat the disease. Despite this recent success, there is still an urgent need for effective treatments across the full spectrum of this complex cancer.

As a world-class academic medical center dedicated exclusively to the understanding and treatment of cancer, MSK is uniquely positioned to answer the most difficult questions and uncover new therapies that improve outcomes for people with lymphoma.

Enhance Immunotherapies
Lymphomas are broadly divided into two groups: Hodgkin lymphoma, a less prevalent diagnosis that is distinguished by the presence of a type of B cell called Reed-Sternberg cell, and non-Hodgkin lymphoma, a more common form that arises from B cells or T cells. The cancer can be aggressive and require immediate treatment, or it can be slow-moving, may not need medical attention right away, and can be monitored attentively, sometimes for many years. Non-Hodgkin lymphoma is the seventh most common cancer in men and the sixth most common in women. It is responsible for approximately 20,000 deaths every year in the United States.

The diversity of subtypes in lymphoma is one of the greatest challenges for physicians and scientists when it comes to determining treatment plans. Recognizing even the smallest differences is essential to improving lymphoma drugs and prolonging survival.
Lymphoma research has flourished in the last 20 years, and MSK has been at the forefront of the field. Leading the effort is Steven A. Greenberg Chair Gilles Salles, MD, PhD, Chief of MSK’s Lymphoma Service. An international leader in the development of novel therapeutics for lymphoma, Dr. Salles has been involved in many large multinational clinical trials that have led to FDA approval of new treatments.

Dr. Salles cites immunotherapy, the revolutionary approach that uses the body’s own immune system to fight cancer, as key to recent breakthroughs in treatment. It is especially effective in people with B cell lymphoma, which accounts for 80% of non-Hodgkin lymphoma cases. Monoclonal antibodies, man-made proteins designed to bind to a specific target on a cell and trigger an immune response to destroy cancer, have drastically improved outcomes for people with aggressive B cell lymphoma and extended the lives of people with slow-moving or indolent B cell lymphoma. Chimeric antigen receptor (CAR) T cell therapy, a breakthrough pioneered by MSK scientists that involves genetically engineering a patient’s own immune cells to recognize and kill cancer cells, has shown success in treating people with aggressive B cell lymphoma who have failed two lines of therapy. CAR T cell therapy is effective in other lymphomas and blood cancers as well.

Discoveries made at MSK are also improving quality of life for people with lymphoma. Physicians now look at the whole patient, considering personal factors like their age and overall health, and treatments are moving away from harsh chemotherapies toward immune-based and targeted therapies that are more effective and less toxic.

“Our research is an ongoing story,” Dr. Salles says, “one that continues to develop and bring new insights every day about a very complex cancer.”
Exploring the Next Breakthrough

MSK scientists are changing the landscape for lymphoma. Investing in lab-based and clinical research at MSK will accelerate innovations and support our researchers as they:

**Enhance Immunotherapies**

Immunotherapy is one of the most promising ways to treat and ultimately cure cancer, and MSK is a world leader in the field. While many people benefit from CAR T cell therapy, some experience severe reactions that impact their health or interfere with the completion of treatment. MSK scientists are developing the next generation of CAR T cells to improve efficacy and diminish the frequency of harmful side effects.

In addition, our experts are exploring a subclass of drugs called bispecific antibodies, which target tumor cells while harnessing powerful components of the body’s immune system. MSK research has been instrumental in the FDA approval of three bispecific antibody drugs since December 2022. Our scientists are continuing to pursue a deeper understanding of the characteristics of bispecific antibodies, specifically how they activate immune cells in the body and what leads some people to be resistant to them.

**Seek to Understand Tumor Response to Cancer Therapies**

Researchers in labs across MSK are gaining new insights into the genetic makeup and progression of lymphoma and are determined to use this information to craft more effective treatments for every form of the disease.

One of their biggest resources is MSK-IMPACT® Heme, a sequencing test that analyzes 400 genes found in blood cancers. MSK scientists have used the test to analyze more than 2,300 lymphoma tumors in patients. The data collected helps them to evaluate tumors’ vulnerability to cancer drugs, shape individualized and targeted treatment plans, determine if a patient is a good candidate for a clinical trial, and further their understanding of the different classes of lymphoma.

In addition, MSK scientists are exploring the epigenetic code in cells and its relation to cancer development. Epigenetic factors influence how genes prompt cells to acquire certain functions, and abnormalities in this process can have adverse effects and cause cancer. Knowing the epigenetic code is damaged in people with lymphoma, MSK researchers are investigating how new drugs or new combinations of drugs can target this pathway.

**Expand Clinical Trials**

Clinical trials determine the safety and efficacy of a treatment, provide information on potential side effects, advance knowledge around a disease, and ultimately lead to new drug approvals. As one of the most active clinical trial programs in the world, MSK has helped to develop most of today’s FDA-approved lymphoma drugs.

Dozens of clinical trials for a diverse range of lymphomas are underway at MSK. One such trial is a phase 1 study for people with diffuse large B cell lymphoma, the most common type of non-Hodgkin lymphoma, that tests CAR T cells made with the genome-editing tool CRISPR/Cas9, a technology that allows researchers to precisely target and modify specific genes to further enhance the effectiveness of CAR T cells.

In another phase 2 clinical trial, MSK scientists are exploring a bispecific antibody in people with follicular lymphoma, a type of indolent non-Hodgkin lymphoma, to replace the classical cytotoxic chemotherapies used for decades. This novel therapy may enhance the ability of the patient’s own T cells to destroy cancer cells.

Multiple other phase 1 and phase 2 studies are evaluating combinations of bispecific antibodies with other drugs that may enhance their activity, to increase the proportion of patients who can be cured.
Marc Ladanyi, Molecular Geneticist; Chief, Molecular Diagnostics Service, and Ryma Benayed, Molecular Geneticist
How You Can Move Progress Forward

The Society of Memorial Sloan Kettering Cancer Center will once again champion extraordinary breakthroughs in science. Philanthropy drives innovation and impacts every phase of the research process, from its earliest stages in the lab to its later investigations in clinical trials.

A gift to this year’s campaign, “Advancing Lymphoma Research,” will accelerate progress at MSK and support scientists as they gain a deeper understanding of the diverse biology of lymphoma and discover more effective treatments for people at MSK and beyond.
The Society of MSK
2023-2024 Administrative Board

President
Muffie Potter Aston

Vice Presidents
Travis Acquavella
Claire Capello
Courtney Corletto

Treasurer
Palmer Jones O’Sullivan

Assistant Treasurer
Jessie Kisling

Secretary
Robyn Joseph

Assistant Secretary
Martha Sharp

Past President
Mrs. Peter D. Jones
Karen Thornwell May

Members-at-Large
Allison Aston
Veronica Swanson Beard
Maria von Bothmer
Catherine Carey
Mrs. Kevin C. Coleman
Mrs. Archibald Cox, Jr.
Mary McDonnell Davidson
Kate Davis
Lisa Errico
Gretchen Gunlocke Fenton
Ruth G. Fleischmann
Mrs. Robert M. Gardiner
Sallie Giordano
Eugenie Niven Goodman
Shoshanna Gruss
Leslie Heaney
Gillian Hearst
Shabnam Henry
Jennifer James
Victoria Greenleaf Kempner
Anna Kennedy
Mrs. Michael Kennedy
Martha Lamphere
Patricia Herrera Lansing
Kamie Lightburn
Stephanie Loeffler
Mrs. José Luis Los Arcos
Rebekah McCabe
Anjali Melwani
Carolina de Neufville
Joanna Baker de Neufville
Dara O’Hara
Jennifer Gaffney Oken
Claudia Taylor Overstrom
Marcie Pantzer
Mrs. Richard T. Perkin
Emilia Fanjul Pfeiffer
Betsy Pitts
Mrs. Louis Rose
Hope Geier Smith
Annie Taube
Ferebee Taube
Amanda Taylor
Mrs. Andrew S. Thomas
Virginia W. Tomson
Amanda Waldron
Naomi Walezky

Sustaining Board
Mrs. James Halsey Bell
Tory Burch
Mrs. Michael Carr
Nancy Coffey
Dianne G. Crary
Jennifer Creel
Mrs. James F. Curtis III
Mrs. Michael J.A. Darling
Mrs. James H. Dean
Mrs. Hilary Dick
Antonia Paepcke DuBrul
Weebb Egerton
Mrs. Thomas J. Fahey, Jr.
Stephanie Fairchild
Mrs. Thomas M. Fitzgerald III
Mrs. Lars Forsberg
Elizabeth Kirby Fuller
Mrs. Thomas S. Glover
Mrs. Roberto de Guardiola
Alexia Hamm Ryan
Mrs. John S. Hilson
Mrs. Ann F. Jeffery
Suzie Kovner
Mrs. Brian A. McCarthy
Elizabeth G. Miller
Mrs. Minot K. Milliken
Courtney Moss
Joyce L. Moss
Mrs. Samuel F. Pryor IV
Mrs. Bambi Putnam
Mrs. Benjamin M. Rosen
Mrs. Paul C. Schorr IV
Kitty Sherrill
Evelyn Angevine Sillia
Mrs. Sean P. Smith

Past Presidents
Kate Allen
Mrs. Coleman P. Burke
Mrs. Edwin M. Burke
Mrs. William M. Carson
Mrs. Bruce A. Gimbel
Martha Vietor Glass
Mrs. Peter S. Gregory
Alison Barr Howard
Mrs. Arie L. Kopelman
Mrs. Thomas V. Leed
Mrs. Derek L. Limbocker
Jean Remmel Little
Mrs. Frank A. Metz, Jr.
Mrs. Bijan Safai
Lavinia Branca Snyder

Founder
Mrs. Edward C. Delafield

2023-2024
Associates Committee

Chair
Austen Cruz

Vice Chairs
Marcella Hymowitz
Meghan Klopp
Marisa Rose van Bokhorst

Committee
Julia Amory
Abigail Baratta
Francesca Bodini
Jean Altier Bohm
Lili Buffett
Fischer Cherry
Lindsey Coleman
Krista Corl
Helena Martinez Cornell
Melissa Crandall
Mimi Ritzen Crawford
Alix C. Creel
Caroline Brooks Melly
Crovatto
Nathalie Pierrepont Danilovich
Beth Blake Day
Mary Dillow
Ali Edwards
Mary Carlisle Gambill
Mercedes de Guardiola

Barkley Hickox
Breanna Khoury
Sevda Kleinman
Elizabeth Kurpis
Amory McAndrew
Candice Miller
Whitney Mogavero
Kimberly Nemser
Erin O’Connor
Betsy Pepe
Annelise Peterson
Isabel Boswell Phillips
Candice Postel
Starrett Ringbom
Anne Roy
Charlotte Sethness
Whitney Schwartz
Lesley Vecsler
Rickie De Sole Webster
Brent Neale Winston
Sara Zilkha
1233 York Avenue, Suite b-101
New York, NY 10065

General Information
212-639-7972

Make an Appointment
800-525-2225

Visit Us Online:
https://giving.mskcc.org/society
Instagram: @TheSocietyofMSK